POM121C

Across TCGA pan-cancer cohorts, POM121C Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated POM121C data layer compared with 25 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher POM121C Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated POM121C expression acts as an unfavorable survival marker.

BRCA, ESCA, and LGG are the cancer types where POM121C Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	III,IV	0.106	0.906	<.001	38	view →
ESCA	DFS	Median	II,III,IV	0.107	0.522	.012	12	view →
LGG	OS	Median	All	0.192	0.799	<.001	6	view →
ACC	OS	Median	All	0.118	0.624	.038	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LIHC	OS	Median	All	0.215	0.690	.013	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

POM121C–BRCA (OS)

Open the BRCA breakdown →